Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes

2011 ◽  
Vol 407 (1) ◽  
pp. 153-157 ◽  
Author(s):  
Soo Jin Yang ◽  
Jung Mook Choi ◽  
Lisa Kim ◽  
Byung-Joon Kim ◽  
Jin Hee Sohn ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Pancreatic Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Chronic Administration ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Pancreatic Beta Cell Mass

Is Defective Pancreatic Beta-cell Mass Environmentally Programmed in Goto-Kakizaki Rat Model of Type 2 Diabetes?

Pancreas ◽  
2006 ◽  
Vol 33 (4) ◽  
pp. 412-417 ◽  
Author(s):  
Sophie Calderari ◽  
Marie-No??lle Gangnerau ◽  
Marie-Jos?? Meile ◽  
Bernard Portha ◽  
Patricia Serradas
Keyword(s):  
Type 2 Diabetes ◽  
Beta Cell ◽  
Rat Model ◽  
Pancreatic Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Pancreatic Beta Cell Mass

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

2000 ◽  
pp. 717-725 ◽  
Author(s):  
R Perfetti ◽  
P Merkel
Keyword(s):  
Beta Cell ◽  
Cell Function ◽  
Pancreatic Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Glucagon Secretion ◽  
Insulin Biosynthesis ◽  
Gut Hormone ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 (GLP-1) is a gut hormone synthesized by post-translational processing in intestinal L-cells, and it is released in response to food ingestion. GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion. GLP-1 has also been shown to have a pro-satiety effect. In addition, it has been demonstrated that a long-term infusion with GLP-1, or exendin-4, a long-acting analog of human GLP-1, increases beta-cell mass in rats. In conclusion, GLP-1 appears to regulate plasma glucose levels via various and independent mechanisms. GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.

Difference in Hepatic Steatosis and Pancreatic Beta-Cell Mass between Dapagliflozin and Insulin Glargine Treatment at Comparable Levels of Glycemic Control

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1862-P
Author(s):  
KAZUNO OMORI ◽  
AKINOBU NAKAMURA ◽  
HIDEAKI MIYOSHI ◽  
KIYOHIKO TAKAHASHI ◽  
NAOYUKI KITAO ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Beta Cell ◽  
Insulin Glargine ◽  
Hepatic Steatosis ◽  
Pancreatic Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Pancreatic Beta Cell Mass
Sign in / Sign up

Export Citation Format

Share Document